Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus
Public ClinicalTrials.gov record NCT00877929. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An 8-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 80 + Amlodipine 10mg Versus Amlodipine 10 mg Monotherapy as First Line Therapy in Type 2 Diabetes Patients With Hypertension.
Study identification
- NCT ID
- NCT00877929
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 706 participants
Conditions and interventions
Conditions
Interventions
- Amlodipine 10 Drug
- Telmisartan 80 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2009
- Primary completion
- Apr 30, 2010
- Completion
- Not listed
- Last update posted
- Mar 11, 2014
Started 2009
United States locations
- U.S. sites
- 15
- U.S. states
- 9
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1235.21.901 Boehringer Ingelheim Investigational Site | Long Beach | California | — | — |
| 1235.21.907 Boehringer Ingelheim Investigational Site | Tustin | California | — | — |
| 1235.21.913 Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | — | — |
| 1235.21.910 Boehringer Ingelheim Investigational Site | Hollywood | Florida | — | — |
| 1235.21.903 Boehringer Ingelheim Investigational Site | Pembroke Pines | Florida | — | — |
| 1235.21.905 Boehringer Ingelheim Investigational Site | Tucker | Georgia | — | — |
| 1235.21.916 Boehringer Ingelheim Investigational Site | Olive Branch | Mississippi | — | — |
| 1235.21.915 Boehringer Ingelheim Investigational Site | Hickory | North Carolina | — | — |
| 1235.21.906 Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | — | — |
| 1235.21.902 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 1235.21.904 Boehringer Ingelheim Investigational Site | Penndel | Pennsylvania | — | — |
| 1235.21.908 Boehringer Ingelheim Investigational Site | Carrollton | Texas | — | — |
| 1235.21.909 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1235.21.912 Boehringer Ingelheim Investigational Site | Killeen | Texas | — | — |
| 1235.21.911 Boehringer Ingelheim Investigational Site | Ettrick | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00877929, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 11, 2014 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00877929 live on ClinicalTrials.gov.